Structures by: Shaibah M. A.
Total: 18
Clozapinium hydrogen bis(3,5-dinitrobenzoate)
C18H20ClN4,C7H3N2O6,C7H4N2O6
Acta Crystallographica Section E (2020) 76, 10 1629-1633
a=7.4102(6)Å b=24.629(2)Å c=18.4460(10)Å
α=90° β=98.478(6)° γ=90°
1-(4-Bromophenyl)-3-[4-(prop-2-ynyloxy)phenyl]prop-2-en-1-one
C18H13BrO2
Acta Crystallographica Section E (2020) 76, 3 360-365
a=18.286(6)Å b=14.277(4)Å c=5.8489(17)Å
α=90° β=94.521(7)° γ=90°
1-(4-Chlorophenyl)-3-[4-(prop-2-ynyloxy)phenyl]prop-2-en-1-one
C18H13ClO2
Acta Crystallographica Section E (2020) 76, 3 360-365
a=17.990(3)Å b=14.2529(16)Å c=5.8661(8)Å
α=90° β=94.419(4)° γ=90°
(<i>RS</i>)-3-(4-Bromophenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C19H16BrN3OS
Acta Crystallographica Section E (2020) 76, 3 360-365
a=15.1255(13)Å b=6.0426(5)Å c=21.026(2)Å
α=90° β=110.555(3)° γ=90°
(<i>RS</i>)-3-(4-Chlorophenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C19H16ClN3OS
Acta Crystallographica Section E (2020) 76, 3 360-365
a=15.0182(9)Å b=6.0579(3)Å c=20.8286(12)Å
α=90° β=110.573(2)° γ=90°
(<i>RS</i>)-3-(4-Methoxyphenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C20H19N3O2S
Acta Crystallographica Section E (2020) 76, 3 360-365
a=11.7852(15)Å b=7.5345(11)Å c=20.599(3)Å
α=90° β=93.555(4)° γ=90°
3-(3-Methyl-5-phenoxy-1-phenyl-1<i>H</i>-pyrazol-4-yl)-1-(thiophen-2-yl)prop-2-en-1-one
C23H18N2O2S
Acta Crystallographica Section E (2020) 76, 1 48-52
a=9.6158(5)Å b=19.8846(11)Å c=10.3773(6)Å
α=90° β=93.712(2)° γ=90°
3-[3-Methyl-5-(2-methylphenoxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]-1-(thiophen-2-yl)prop-2-en-1-one
C24H20N2O2S
Acta Crystallographica Section E (2020) 76, 1 48-52
a=9.4336(4)Å b=20.6071(9)Å c=10.5866(4)Å
α=90° β=93.106(2)° γ=90°
Trihexyphenidylium 3,5-dinitrobenzoate
C20H32NO,C7H3N2O6
Acta Crystallographica Section E (2019) 75, 2 292-298
a=11.2743(12)Å b=11.2898(12)Å c=12.6478(13)Å
α=111.9230(10)° β=114.3250(10)° γ=95.9030(10)°
[3-(2-Chloro-9<i>H</i>-thioxanthen-9-yl)propyl]dimethylammonium hydrogen bis(3,5-dinitrobenzoate)
C18H19ClNS,C7H3N2O6,C7H4N2O6
Acta Crystallographica Section E (2019) 75, 2 292-298
a=11.3454(8)Å b=24.3857(16)Å c=11.6098(8)Å
α=90° β=93.6910(10)° γ=90°
2-Amino-4,4,7,7-tetramethyl-3a,5,6,7a-tetrahydrobenzothiazol-3-ium 4-methylbenzoate
C11H19N2S,C8H7O2
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=10.1879(5)Å b=11.6149(5)Å c=8.7790(4)Å
α=90° β=113.480(6)° γ=90°
2-Amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium 4-bromobenzoate
C11H19N2S,C7H4BrO2
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=10.2506(5)Å b=11.5855(4)Å c=8.8269(4)Å
α=90° β=113.807(6)° γ=90°
2-Amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium 3,5-dinitrobenzoate
C11H19N2S,C7H3N2O6
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=17.3232(6)Å b=5.84087(17)Å c=21.0876(8)Å
α=90° β=109.875(4)° γ=90°
Bis(2-amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium) fumarate
2(C11H19N2S),C4H2O42
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=9.0259(6)Å b=14.7314(11)Å c=11.1993(8)Å
α=90° β=101.943(6)° γ=90°
4-(Benzhydryloxy)-1-[4-(4-<i>tert</i>-butylphenyl)-4-oxobutyl]piperidinium 3,5-dinitrobenzoate
C32H40NO2,C7H3N2O6
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 10 1513-1516
a=5.9168(3)Å b=28.3733(12)Å c=21.0782(11)Å
α=90° β=97.836(5)° γ=90°
<i>N</i>,<i>N</i>-Dimethyl-[2-(2,2-diphenyl)-2-prop-2-ynyloxyacetoxy]ethylamine
C21H23NO3
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 10 1488-1492
a=9.2545(9)Å b=21.7246(19)Å c=9.4531(9)Å
α=90° β=94.763(9)° γ=90°
<i>N</i>,<i>N</i>-Dimethyl-[2-(2,2-diphenyl)-2-prop-2-ynyloxy\ acetoxy]ethylammonium 2,4,6-trinitrophenolate
C21H24NO3,C6H2N3O7
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 10 1488-1492
a=7.5208(3)Å b=8.3919(3)Å c=22.2282(7)Å
α=85.099(3)° β=84.294(3)° γ=75.117(3)°
Bis(2-amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium) succinate--2-amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium hydrogen succinate 4,4,7,7-tetramethyl-3a,5,6,7a-tetrahydrobenzothiazol-2-ylamine (1/1)
1.5(C11H19N2S),0.5(C4H4O42),0.5(C4H5O4),0.5(C11H18N2S)
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=8.9437(3)Å b=14.7253(4)Å c=11.2676(4)Å
α=90° β=100.493(3)° γ=90°